A Study to Assess the Relative Bioavailability of 3 Different Formulations Under Fasted and Fed Condition
Status:
Completed
Trial end date:
2019-09-18
Target enrollment:
Participant gender:
Summary
This study is intended to assess the relative bioavailability between the (extended-release)
ER8 capsule formulation (the formulation that is currently used for verinurad development)
given under fasted conditions and 2 new capsule formulations of verinurad (A-capsule and
B-capsule) given under fed or fasted conditions. All three capsules target an 8-hour release
profile (extended-release). The highest dose (12 mg) currently tested in participants will be
tested in this study. The study is designed to provide information to optimize the verinurad
part of a fixed dose combination capsule to be used in future development.